Pulmonary Hypertension | Current Treatment: Physician Insights | US | 2019

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients. In PAH patients, phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are most commonly prescribed as first-line treatment, with the more-efficacious prostacyclin therapies used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common. Adempas is the only approved therapy for CTEPH patients. PH is a highly lucrative market despite the relatively small patient population.

QUESTIONS ANSWERED

What is the current patient share of branded therapies such as United Therapeutics’ Orenitram and Remodulin, Actelion’s Opsumit, and Bayer’s Adempas?
What effect has the launch of Actelion’s Uptravi had on treatment decisions?
What are the anticipated changes in prescribing patterns over the next 12 months?
How are specialists utilizing PAH therapies for the treatment of PH WHO Groups 2-5?
What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of PH?
What are the drivers and constraints determining prescribing practices for PH?

Scope

Geography: United States
Primary Research: Survey of 101 U.S. cardiologists / pulmonologists
Key Drugs Covered: Uptravi, Opsumit, Remodulin, Tyvaso, Orenitram, Adempas, sildenafil, tadalafil, iloprost, epoprostenol

Contact sales account_box

Report

Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…

north_east

Report

Insomnia – Current Treatment – Current Treatment: Physician Insights – Insomnia (EU5)

Insomnia is a common sleep disorder characterized by difficulty initiating or maintaining sleep, leading to impaired daytime functioning. Its management is highly personalized, with clinicians…

north_east

Report

Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)

Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…

north_east

Report

Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…

north_east

Report

Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis

China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…

north_east

Product logins

Pulmonary Hypertension | Current Treatment: Physician Insights | US | 2019

Related Market Assessment Reports

Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)

Insomnia – Current Treatment – Current Treatment: Physician Insights – Insomnia (EU5)

Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)

Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)

Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis

Follow us

Contact us